MXPA03000527A - Composiciones y metodos para la terapia y diagnostico de cancer ovarico. - Google Patents

Composiciones y metodos para la terapia y diagnostico de cancer ovarico.

Info

Publication number
MXPA03000527A
MXPA03000527A MXPA03000527A MXPA03000527A MXPA03000527A MX PA03000527 A MXPA03000527 A MX PA03000527A MX PA03000527 A MXPA03000527 A MX PA03000527A MX PA03000527 A MXPA03000527 A MX PA03000527A MX PA03000527 A MXPA03000527 A MX PA03000527A
Authority
MX
Mexico
Prior art keywords
compositions
diagnosis
ovarian cancer
methods
therapy
Prior art date
Application number
MXPA03000527A
Other languages
English (en)
Inventor
Earl Albone
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03000527(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/636,801 external-priority patent/US7202334B1/en
Priority claimed from US09/667,857 external-priority patent/US6699664B1/en
Priority claimed from US09/827,271 external-priority patent/US6962980B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of MXPA03000527A publication Critical patent/MXPA03000527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen composiciones y metodos para la terapia y diagnostico de cancer, tal como cancer ovarico. Las composiciones pueden comprender una o mas proteinas de carcinoma ovarico, porciones inmunogenicas de las mismas, polinucleotidos que codifican tales porciones o anticuerpos o celulas del sistema inmune especificas para tales proteinas. Tales composiciones pueden utilizarse, por ejemplo, para la prevencion y tratamiento de enfermedades tal como cancer ovarico. Se proporcionan ademas metodos para identificar antigenos de tumor que se secretan de carcinomas ovaricos y/u otros tumores. Los polipeptidos y polinucleotidos, como se proporcionan en la presente, pueden utilizarse ademas para el diagnostico y monitoreo de cancer ovarico.
MXPA03000527A 2000-07-17 2001-07-17 Composiciones y metodos para la terapia y diagnostico de cancer ovarico. MXPA03000527A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61774700A 2000-07-17 2000-07-17
US09/636,801 US7202334B1 (en) 1998-12-17 2000-08-10 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/667,857 US6699664B1 (en) 1998-12-17 2000-09-20 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/827,271 US6962980B2 (en) 1999-09-24 2001-04-04 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/884,441 US20020119158A1 (en) 1998-12-17 2001-06-18 Compositions and methods for the therapy and diagnosis of ovarian cancer
PCT/US2001/022635 WO2002006317A2 (en) 2000-07-17 2001-07-17 Compositions and methods for the therapy and diagnosis of ovarian cancer

Publications (1)

Publication Number Publication Date
MXPA03000527A true MXPA03000527A (es) 2004-08-12

Family

ID=27541997

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000527A MXPA03000527A (es) 2000-07-17 2001-07-17 Composiciones y metodos para la terapia y diagnostico de cancer ovarico.

Country Status (19)

Country Link
US (1) US20020119158A1 (es)
EP (2) EP2022800A3 (es)
KR (1) KR20080068143A (es)
CN (1) CN100439395C (es)
AT (1) ATE410446T1 (es)
AU (3) AU2001276973B2 (es)
BR (1) BR0112542A (es)
CA (1) CA2418391A1 (es)
CZ (1) CZ2003440A3 (es)
DE (1) DE60136099D1 (es)
DK (1) DK1349870T3 (es)
HU (1) HUP0302532A2 (es)
IL (1) IL153996A0 (es)
MX (1) MXPA03000527A (es)
NO (1) NO20030211L (es)
NZ (2) NZ551214A (es)
PL (1) PL366575A1 (es)
PT (1) PT1349870E (es)
WO (1) WO2002006317A2 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012758A1 (en) 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1445318A2 (en) * 2000-08-24 2004-08-11 Genetech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002254615A1 (en) * 2001-04-17 2002-10-28 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
US7309760B2 (en) 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
JP2006512044A (ja) * 2002-03-07 2006-04-13 アバロン ファーマシューティカルズ，インコーポレイテッド 化学療法のための標的としての癌関連遺伝子
EP1576111A4 (en) * 2002-06-07 2006-10-18 Avalon Pharmaceuticals CANCER-ASSOCIATED GENE AS A TARGET FOR CHEMOTHERAPY
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
US7304149B2 (en) 2002-06-20 2007-12-04 Washington University In St. Louis BTLA nucleic acids
US7202346B2 (en) 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
ES2320443T3 (es) * 2002-09-30 2009-05-22 Oncotherapy Science, Inc. Genes y polipeptidos relacionados con canceres pancreaticos humanos.
PT2891666T (pt) * 2002-10-16 2017-09-22 Purdue Pharma Lp Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização
CA2505919A1 (en) * 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
JP4884224B2 (ja) * 2003-05-09 2012-02-29 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
US8207311B2 (en) * 2003-05-16 2012-06-26 Diadexus, Inc. Ovr115 antibody compositions and methods of use
US7479546B2 (en) * 2003-06-27 2009-01-20 Diadexus, Inc. Pro104 antibody compositions and methods of use
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP1817055B1 (en) * 2004-11-10 2012-12-26 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8323645B2 (en) 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
CN101948541B (zh) * 2005-06-20 2014-08-06 健泰科生物技术公司 用于肿瘤诊断和治疗的组合物和方法
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ568015A (en) * 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
MX2012000468A (es) * 2009-07-09 2012-03-07 Abraxis Bioscience Llc Composiciones antisentido de proteina acida secretada y rica en cisteina (sparc) y usos de las mismas.
IN2012DN03025A (es) 2009-09-09 2015-07-31 Ct Se Llc
CA3188287A1 (en) 2010-03-26 2011-09-29 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
EP2750713B1 (en) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
PL2906253T3 (pl) 2012-10-12 2019-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
CN105102068B (zh) 2012-10-12 2018-06-01 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗体结合物
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20230321A1 (es) 2015-07-01 2023-02-22 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
MA46717A (fr) * 2016-10-11 2019-09-11 Bluebird Bio Inc Variantes de l'endonucléase homing tcra
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
NZ761175A (en) 2017-08-18 2024-07-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
UA128472C2 (uk) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 антитіла і методи їх використання
TW201920192A (zh) 2017-09-20 2019-06-01 韓商Ｐｈ製藥公司 泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN112898425B (zh) * 2021-01-28 2022-09-09 姜国胜 一种amh纳米抗体、试剂盒及在生殖领域的应用
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3040469B2 (ja) 1990-10-18 2000-05-15 セルプロ インコーポレイテッド 可撓性容器を用いて粒子を分離する装置及び方法
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5986170A (en) 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
IL139686A0 (en) * 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000012758A1 (en) * 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
WO2001094641A2 (en) * 2000-06-09 2001-12-13 Idec Pharmaceuticals Corporation Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
MXPA02012749A (es) * 2000-06-30 2003-10-06 Amgen Inc Moleculas semejantes a b7 y sus usos.

Also Published As

Publication number Publication date
CA2418391A1 (en) 2002-01-24
NO20030211D0 (no) 2003-01-16
KR20080068143A (ko) 2008-07-22
IL153996A0 (en) 2003-07-31
EP1349870A2 (en) 2003-10-08
CN1529713A (zh) 2004-09-15
NO20030211L (no) 2003-03-14
CZ2003440A3 (cs) 2003-12-17
EP2022800A3 (en) 2009-02-25
PT1349870E (pt) 2009-01-19
AU2007202776A1 (en) 2007-07-12
BR0112542A (pt) 2005-04-26
DE60136099D1 (de) 2008-11-20
AU2007202776B2 (en) 2011-03-24
EP1349870B1 (en) 2008-10-08
HUP0302532A2 (hu) 2003-10-28
AU7697301A (en) 2002-01-30
NZ578927A (en) 2010-10-29
WO2002006317A2 (en) 2002-01-24
PL366575A1 (en) 2005-02-07
EP2022800A2 (en) 2009-02-11
AU2001276973B2 (en) 2007-06-14
DK1349870T3 (da) 2009-02-09
US20020119158A1 (en) 2002-08-29
CN100439395C (zh) 2008-12-03
WO2002006317A3 (en) 2003-07-03
ATE410446T1 (de) 2008-10-15
NZ551214A (en) 2008-05-30

Similar Documents

Publication Publication Date Title
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2002016413A3 (en) Cripto tumour polypeptide
WO2001008636A8 (en) Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
WO1999037775A3 (en) Compositions and methods for detecting and treating breast cancer
EP1351967A4 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου
WO2001098339A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO1999054466A3 (en) Colon cancer-associated antigens and their diagnostic and therapeutic uses
WO2003022126A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001092525A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO1999037778A3 (en) Compositions and methods for detecting and treating prostate cancer